Log In
BCIQ
Print this Print this
 

Tucotuzumab celmoleukin

  Manage Alerts
Collapse Summary General Information
Company Merck KGaA
DescriptionFusion protein of the humanized mAb tucotuzumab and an interleukin-2 (IL-2; celmoleukin)
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase II
Standard IndicationSmall cell lung cancer
Indication DetailsTreat small cell lung cancer (SCLC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today